The point-of-care diagnostics market is estimated to be over $11 billion in size and growing at an annual rate over 10%. Components include consumer self-testing, primary care (physician's office) testing and hospital emergency room testing.
Test categories include:
- Blood glucose
- Blood gas/electrolytes
- Hematology
- Pregnancy/fertility
- Tumor markers
- Cardiology
- Coagulation
- Infectious Disease
- Drugs of Abuse
- Clinical Chemistry/Urinalysis
Addressing the needs of point-of-care diagnostics, whether the sample be saliva, urine, blood or some other body fluid, is a logical extension of Cantimer's technical capabilities. The company has already demonstrated “proof of concept” in the application of its technology to the detection and measurement of single strand DNA, Antigen/Antibody complexes, a virus (Vaccinia), electrolytes such as sodium and potassium, pH and a broad array of analytes including ethanol, urea and glucose.
Cantimer welcomes enquiries regarding its platform and/or potential new applications. If you are interested in licensing the technology or partnering with Cantimer in the development of sensors or devices for proprietary assays, please contact:
Ray Stewart, Ph.D.
Chief Technology Officer
rstewart@cantimer.com
(650) 474-0500, x302